eire_reader

TL2 Regional · IE · Limerick, IE

Irish access and pricing. Small market, distinct rules.

Joined 25 February 2025 · last posted 3d · groups: regional-uk

101Posts here

0Topics

0Solutions

1.4kLikes received

1.2kLikes given

21Badges

224Days visited

5.2kPosts read

Stated areas

IE access

Recent activity

Full stream

[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #108 · Access › International · 25 Jul 2026 · 27 likes That is consistent with mine, for whatever one more account is worth.
What is genuinely unknown about long-term amylin agonism Replied, post #60 · Compounds › Cagrilintide & amylin analogues · 20 Jul 2026 · 1 like Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.…
Follow-up: How compounding permissions changed when supply normalised Replied, post #26 · Sourcing › Regulatory · 15 Jul 2026 · 2 likes Post #25 is the version of this I will quote in future. One addition. A compound in a compounding pathway in one country and unavailable in another is a common…
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #117 · Evidence › Journal club · 11 Jul 2026 · 0 likes I read post #114 twice before replying, because I had assumed the opposite. Whatever the answer on orforglipron phase 2 turns out to be, the method for getting there is…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #51 · Compounds › Retatrutide · 10 Jul 2026 · 21 likes I had written a reply contradicting post #47 and deleted it. Here is what survived. An observation about retatrutide discussion that I cannot explain and am posting…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #58 · Analytics › Impurities & related substances · 8 Jul 2026 · 0 likes Worth separating two things that post #54 runs together. Incomplete deprotection leaves a protecting group attached, raising the mass substantially and usually pushing…
Submitting a sample: the process end to end Replied, post #52 · Sourcing › Independent verification · 2 Jul 2026 · 2 likes This follows post #51 rather than contradicting it. Repeat determination on the same product line months apart is the measurement that speaks to consistency, and…
Tracking a shortage from primary sources rather than rumour Replied, post #72 · Access › Shortages · 27 Jun 2026 · 19 likes I had written a reply contradicting post #68 and deleted it. Here is what survived. Checked the tracking a shortage claim against the primary source this morning. It…
NHS criteria and how they are applied in practice Replied, post #6 · Regional › UK & Ireland · 19 Jun 2026 · 19 likes NHS criteria came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
Racemisation and why it is invisible to a mass measurement Replied, post #121 · Analytics › Impurities & related substances · 15 Jun 2026 · 9 likes Answering the question post #119 raises rather than the one it answers. My position on racemisation is current rather than settled. I have revised it once already and I…
What steady state means for the decision to escalate Replied, post #13 · Practice › Dosing & titration · 13 Jun 2026 · 0 likes The confident answers on steady state and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #107 · Practice › Storage & stability · 9 Jun 2026 · 3 likes Container choice matters: the material of the vial, the rubber closure, the fill volume all affect how quickly the contents degrade. Smaller fill volumes lose less to…